text:
Review: Fibaro's 'The Button' Adds Physical Control Options to Your HomeKit Setup
Friday November 16, 2018 6:36 PM PST by Juli Clover
"The Button" from Fibaro is the latest HomeKit accessory that's designed to add physical control options to your HomeKit setup, making it easier to access HomeKit devices without an iOS device or HomePod.
Design wise, The Button looks like you might expect something called "The Button" to look. Made of smooth plastic, it has a small round base that holds a slightly larger button that depresses to activate HomeKit commands.
I like the look of the button, and it offers a satisfying button-like press that's better than some of the other competing button and tap-style devices that offer physical HomeKit controls. The button I reviewed was white, but it is also available black and red.
The Button supports just three gestures: a single click, a double click, and a press and hold. This limits what can be done with The Button, so a household may need more than one if there are a lot of HomeKit products and you want granular control over each one.
You can attach the button to a wall or a desk using included adhesive or by nailing the plastic mounting plate into the wall. You can also just use it sans adhesive or mounting plate if it's just sitting on a desk or nightstand, or if you want to be able to move it around.
There is no light to indicate that The Button is turned on and has power, but you can enable an audio feedback option in the settings section of the Fibaro app to have it beep when a button press is activated.
Setting up The Button is a little more involved than the setup process for some other HomeKit products. You need to press down and rotate The Button in a counterclockwise direction (like a childproof pill bottle) to open it up to remove the battery blocker.
Once open, you need to take out the user-replaceable 1/2AA battery that powers the accessory to remove the small piece of paper before putting the battery back in place and closing it back up. From there, you can download the Fibaro app or the Home app and add it to a HomeKit setup using the QR code in the manual or on the bottom of The Button.
I thought the Fibaro app was one of the worst HomeKit apps I've ever used. It's cluttered, has an unintuitive UI, and uses a color scheme that makes text hard to read. It also has no real instructions on programming The Button, which is going to be confusing for those who are new to HomeKit and unfamiliar with automations.
Most users will probably be better off controlling and programming The Button with the Apple Home app, where you can more easily assign Scenes and automations to each button press.
With The Button, you can do things like activate a specific scene to turn off all of the lights in the house at night, lock the door, and turn down the thermostat, or turn on all the lights in the morning and turn up the thermostat, all depending on which HomeKit devices you have installed and what you want The Button to do.
I set a single press to turn off all of the lights in my office with the exception of my night lights, and a double press turns them all back on in the morning. A long press sets an evening scene that dims the lights. The Button can do a huge variety of things depending on the HomeKit products you own, but I've found it most useful for lighting. It can turn lights on and off, dim lights, change colors, and more.
The Button was always responsive during my testing over the past couple of weeks, with each of the three button presses clearly activating each scene assigned to it. I didn't run into any connectivity problems or other issues while using The Button, which is always a plus.
When you just want to turn the lights on or execute a quick action, it can be a hassle to pull out your iPhone and open up the Home app or use Siri. Physical control products like The Button add a lot of convenience to a HomeKit setup, and they're a must have for guests who don't have access to your HomeKit devices but need to control something simple like a light.
At $60, The Button is more expensive than competing options like the Eve Button, or the Hue Tap, but it's on par with the Logitech Pop and it's arguably one of the more fun button devices you can purchase given its intuitive button design and the range of colors it's available in.
You can purchase Fibaro's The Button from Amazon or from the Apple Store for $59.99.
Tag: HomeKit Guide
Will.O.Bie
Reminds me of this...
twistedpixel8
They cost *how much*?!
H3LL5P4WN
I kinda of dig the novelty of the button... but $60 is insane for a joke product.
dwaltwhit
I'm a buyer at $25 or $30 but $60? I'll pass unless it goes on a deep discount.
zantafio
the jokes keep writing themselves....
...nailing the plastic mounting plate into the wall...
There are these incredible things called "screws" that do a substantially better job at attaching things to a wall than nails. Game changing.


No sommelier? No problem! Open wine bottles like a pro with the Ozeri Prestige Electric Wine Opener! - Susan Said... WHAT?!
It's finally Friday and tonight I am headed to a dinner party with some old friends. This gregarious couple is well-known for their hospitality – from large holiday parties, to intimate get togethers, to massive bonfires in the fall!
Since they entertain so frequently, finding a unique hostess gift is somewhat tricky. But tonight, I have just thing — an Ozeri Prestige Electric Wine Opener!
Why electric? This new wine opener makes opening wine bottles oh-so-easy for the always busy host or hostess. No more struggling with a corkscrew (potentially breaking the cork off into your wine). Instead, open bottles easily with just the gentle push of a button. Plus, the Ozeri Prestige Electric Wine Opener works equally well on both natural and synthetic corks.
Plus, it's lightweight and cordless. So, it's perfect for use at outdoor events like tailgates, regattas, pool parties, and barbeques.
Although it is lightweight enough to pack on a picnic, like all Ozeri products, this wine opener is really sturdy. Since it was designed not only for in-home use, but also for use in busy restaurants, this opener was built to last!
To see more great Ozeri products for the kitchen and bath, as well as trademark fitness gear, visit Ozeri.
DISCLAIMER: I received an Ozeri Prestige Electric Wine Opener free in order to fully evaluate the product. Regardless, I only recommend products or services I use personally and believe will be good for my readers.
You cleanse. You buff. You moisturize. But do you remember to tone your skin?
Win Makeup in Collectible Tin by One Direction!
Separator image Posted in FABULOUS INTERIORS and tagged with home and garden gift ideas 2014, hostess gift ideas 2014, Ozeri Prestige Electric Wine Opener, Susan Conforte McNeill, Susan Said What?!, wine gifts for the hostess 2014.


text:
Midland County är ett administrativt område i delstaten Texas, USA, med 136 872 invånare (2010). Den administrativa huvudorten (county seat) är Midland.

Geografi
Enligt United States Census Bureau har countyt en total area på 2 336 km². 2 331 km² av den arean är land och 5 km² är vatten.

Angränsande countyn
 Martin County - norr
 Glasscock County - öster
 Upton County - söder
 Ector County - väster
 Andrews County - nordväst

Källor

redpajama_set_name: RedPajamaWikipedia


text:
Universal Electronics Reports Fourth Quarter and Year-End 2021 Financial Results
Feb 17, 2022 |
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Feb. 17, 2022-- Universal Electronics Inc. (UEI), (NASDAQ: UEIC) reported financial results for the three and twelve months ended December 31, 2021.
"We remain optimistic regarding our growth prospects for the full year, as significant customer and project wins will begin to ship in the back half of the year, although we foresee a particularly challenging start to 2022," said Paul Arling, UEI's chairman and CEO. "Supply chain issues and materials shortages continue to have both a direct and indirect impact on our volumes, as we have been unable to fulfill all the orders in our backlog and our customers have been limited in producing the companion products with which our solutions pair.
"Even with these strong near-term headwinds, our product team continues to succeed in its mission to build the world's most innovative next-generation control products. At CES in January 2022, we introduced our new suite of control products that feature embedded energy harvesting technology combined with chipsets designed to function in extreme low power situations. This will translate to tremendously extended battery life, and some products that may not require changing batteries for the life of the product.
"With more than three decades of experience, we have managed through challenging sales cycles previously. While each period is unique, one factor has always been true – UEI has emerged from difficult periods stronger and better-positioned than before. We are quite confident that, when these macro pressures subside, our steadfast commitment to innovation and customer service will once again deliver long-term growth."
Financial Results for the Three Months Ended December 31: 2021 Compared to 2020
GAAP net sales were $144.9 million, compared to $156.3 million; Adjusted Non-GAAP net sales were $143.9 million, compared to $156.4 million.
GAAP gross margins were 24.9%, compared to 32.7%; Adjusted Non-GAAP gross margins were 28.4%, compared to 33.6%.
GAAP operating loss was $3.3 million, compared to operating income of $12.5 million; Adjusted Non-GAAP operating income was $10.7 million, compared to $19.1 million.
GAAP net loss was $6.3 million, or $0.49 per share, compared to net income of $12.2 million or $0.86 per diluted share; Adjusted Non-GAAP net income was $9.0 million, or $0.68 per diluted share, compared to $16.0 million, or $1.14 per diluted share.
At December 31, 2021, cash and cash equivalents were $60.8 million.
Financial Results for the Twelve Months Ended December 31: 2021 Compared to 2020
GAAP operating income was $23.3 million, compared to $37.3 million; Adjusted Non-GAAP operating income was $58.9 million, compared to $65.5 million.
GAAP net income was $5.3 million, or $0.39 per diluted share, compared to $38.6 million or $2.72 per diluted share; Adjusted Non-GAAP net income was $49.4 million, or $3.59 per diluted share, compared to $53.3 million, or $3.76 per diluted share.
UEI's CFO Bryan Hackworth, stated, "While we expect 2022 to have a challenging start, we remain optimistic regarding our full year and long-term outlook. We believe in UEI's significant intrinsic value, and we expect continued strength in free cash flow for 2022. As a result, our board of directors approved a plan to repurchase an additional 300,000 shares, contingent on price, over the next few months."
For the first quarter of 2022, the company expects GAAP net sales to range between $135 million and $145 million, compared to $150.5 million in the first quarter of 2021. GAAP earnings per diluted share for the first quarter of 2022 are expected to range from ($0.05) to $0.05, compared to GAAP earnings of $0.49 in the first quarter of 2021.
For the first quarter of 2022, the company expects Adjusted Non-GAAP net sales to range between $135 million and $145 million, compared to $150.7 million in the first quarter of 2021. Adjusted Non-GAAP earnings per diluted share are expected to range from $0.46 to $0.56 compared to Adjusted Non-GAAP earnings per diluted share of $0.89 in the first quarter of 2021. The first quarter 2022 Adjusted Non-GAAP earnings per diluted share estimate excludes $0.51 per share related to, among other things, excess manufacturing overhead costs, stock-based compensation, amortization of acquired intangibles, litigation costs, foreign currency gains and losses and the related tax impact of these adjustments. For a more detailed explanation of Non-GAAP measures, please see the Use of Non-GAAP Financial Metrics discussion and the Reconciliation of Adjusted Non-GAAP Financial Results, each located elsewhere in this press release.
The company continues to believe in its long-term growth targets of sales between 5% and 10% and EPS between 10% and 20%.
UEI's management team will hold a conference call today, Thursday, February 17, 2022 at 4:30 p.m. ET / 1:30 p.m. PT, to discuss its fourth quarter and full year 2021 earnings results, review recent activity and answer questions. To access the call in the U.S. please dial 877-843-0414, and for international calls dial 315-625-3071 approximately 15 minutes prior to the start of the conference. The conference ID is 3937268. The conference call will also be broadcast live on the investor section of the UEI website where it will be available for replay for one year. In addition, a replay will be available via telephone for two business days beginning two hours after the call. To listen to the replay, in the U.S. please dial 877-843-0414, and internationally dial 315-625-3071. The access code is 3937268.
In addition to reporting financial results in accordance with generally accepted accounting principles, or GAAP, UEI provides Adjusted Non-GAAP information as additional information for its operating results. References to Adjusted Non-GAAP information are to non-GAAP financial measures. These measures are not required by, in accordance with, or an alternative for, GAAP and may be different from non-GAAP financial measures used by other companies. UEI's management uses these measures for reviewing the financial results of UEI for budget planning purposes and for making operational and financial decisions. Management believes that providing these non-GAAP financial measures to investors, as a supplement to GAAP financial measures, help investors evaluate UEI's core operating and financial performance and business trends consistent with how management evaluates such performance and trends. Additionally, management believes these measures facilitate comparisons with the core operating and financial results and business trends of competitors and other companies.
Adjusted Non-GAAP net sales is defined as net sales excluding the revenue impact of stock-based compensation for performance-based warrants. Adjusted Non-GAAP gross profit is defined as gross profit excluding the impact of additional Section 301 U.S. tariffs on products manufactured in China and imported into the U.S., excess manufacturing overhead costs, including those related to the COVID-19 pandemic, factory transition costs, impairment charges on certain China-based fixed assets, loss on the sale of our Ohio call center, gain on the release from our Ohio call center lease obligation guarantee, stock-based compensation expense, depreciation expense related to the increase in fixed assets from cost to fair market value resulting from acquisitions and employee related restructuring costs. Adjusted Non-GAAP operating expenses are defined as operating expenses excluding stock-based compensation expense, amortization of intangibles acquired, changes in contingent consideration related to acquisitions, costs associated with certain litigation efforts, and employee related restructuring and other costs. Adjusted Non-GAAP net income is defined as net income excluding the aforementioned items, the loss on the sale of our Argentina subsidiary, the reversal of a social insurance accrual and accounts receivable reserve related to our Guangzhou entity, which was sold in 2018, foreign currency gains and losses, the related tax effects of all adjustments and the effect of a reversal of a reserve of an uncertain tax position related to our Guangzhou entity, which was sold in 2018. Adjusted Non-GAAP diluted earnings per share is calculated using Adjusted Non-GAAP net income. A reconciliation of these financial measures to the most directly comparable GAAP financial measures is included at the end of this press release.
About Universal Electronics
Founded in 1986, Universal Electronics Inc. (NASDAQ: UEIC) is the global leader in wireless universal control solutions for home entertainment and smart home devices. We design, develop, manufacture, ship and support control and sensor technology solutions and a broad line of universal control systems, audio video accessories, and intelligent wireless security and smart home products. Our products and solutions are used by the world's leading brands in the video services, consumer electronics, security, home automation, climate control and home appliance markets. For more information, visit www.uei.com.
This press release and accompanying schedules contain "forward-looking statements" within the meaning of federal securities laws, including net sales, profit margin and earnings trends, estimates and assumptions; our expectations about new product introductions; and similar statements concerning anticipated future events and expectations that are not historical facts. We caution you that these statements are not guarantees of future performance and are subject to numerous risks and uncertainties, including those we identify below and other risk factors that we identify in our most recent annual report on Form 10-K for the year ended December 31, 2020, and quarterly and periodic reports we have filed with the Securities Exchange Commission (the "SEC") since then. Risks that could affect forward-looking statements in this press release include: customer and project wins shipping when and in the quantities anticipated by management; supply chain issues and materials shortages growing in magnitude greater than that expected by management; our customers continuing to limit its ordering of our products due to their own supply chain issues and materials shortages; our ability to continue anticipating the needs and wants of our customers, and timely develop and deliver products and technologies that will be accepted by our customers; the continued ordering pattern of our customers as anticipated by management; management's ability to manage its business to achieve its net sales, margins, and earnings through its operating efficiencies, product mix, and gross margin improvement initiatives as guided and as anticipated; our ability to manage our supply chain and logistics interruptions and delays; our ability to enhance and protect the value of our intellectual properties, including our patents and trade secrets, through our licensing and litigation efforts; the effects that natural disasters and public health crises, including the COVID-19 pandemic, have on our business and management's ability to anticipate and mitigate those effects, including the duration, severity and scope of the COVID-19 pandemic, and the actions and restrictions that may be imposed on us and our operations by federal, state, local and international public health and governmental authorities to contain and combat the outbreak and spread of COVID-19, each of which may exacerbate one or more of the aforementioned risks; the impact to our business stemming from the press report and Senate inquiry regarding the Chinese work force used in one of our China factories; effects and uncertainties and other factors more fully described in our reports filed with the SEC; and the effects that changes in or enhanced use of laws, regulations and policies may have on our business including the impact of trade regulations pertaining to importation of our products and the tariffs imposed upon them. Since it is not possible to predict or identify all of the risks, uncertainties and other factors that may affect future results, the above list should not be considered a complete list. Further, any of these factors could cause actual results to differ materially from the expectations we express or imply in this press release. We make these forward-looking statements as of February 17, 2022, and we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Income tax receivable
Deferred income taxes
Accrued compensation
Accrued sales discounts, rebates and royalties
Accrued income taxes
Other accrued liabilities
Operating lease obligations
Contingent consideration
Income tax payable
Common stock, $0.01 par value, 50,000,000 shares authorized; 24,678,942 and 24,391,595 shares issued on December 31, 2021 and 2020, respectively
Treasury stock, at cost, 11,861,198 and 10,618,002 shares on December 31, 2021 and 2020, respectively
Twelve Months Ended December 31,
Interest income (expense), net
Loss on sale of Argentina subsidiary
Accrued social insurance adjustment
Other income (expense), net
Income (loss) before provision for income taxes
Earnings (loss) per share:
Provision for credit losses
Shares issued for employee benefit plan
Employee and director stock-based compensation
Performance-based common stock warrants
Impairment of long-term assets
Loss on sale of Argentina subsidiary, net of cash transferred
Loss on sale of Ohio call center
Accounts receivable and contract assets
Prepaid expenses and other assets
Acquisitions of property, plant and equipment
Acquisitions of intangible assets
Payment on sale of Ohio call center
Net cash used for investing activities
Borrowings under line of credit
Repayments on line of credit
Proceeds from stock options exercised
Treasury stock purchased
Contingent consideration payments in connection with business combinations
Net cash used for financing activities
Effect of foreign currency exchange rates on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental cash flow information:
Income taxes paid
RECONCILIATION OF ADJUSTED NON-GAAP FINANCIAL RESULTS
Net sales:
Net sales - GAAP
Stock-based compensation for performance-based warrants
Adjusted Non-GAAP net sales
Cost of sales:
Cost of sales - GAAP
Section 301 U.S. tariffs on goods imported from China (1)
Excess manufacturing overhead and factory transition costs (2)
Impairment of China-based fixed assets (3)
Loss on sale of Ohio call center (4)
Gain on release from Ohio call center lease obligation guarantee (5)
Stock-based compensation expense
Adjustments to acquired tangible assets (6)
Employee related restructuring
Adjusted Non-GAAP cost of sales
Adjusted Non-GAAP gross profit
Gross margin:
Gross margin - GAAP
)%
Adjusted Non-GAAP gross margin
Operating expenses - GAAP
Amortization of acquired intangible assets
Change in contingent consideration
Litigation costs (7)
Employee related restructuring and other costs
Adjusted Non-GAAP operating expenses
Operating income (loss):
Operating income (loss) - GAAP
Adjusted Non-GAAP operating income
Adjusted Non-GAAP operating income as a percentage of net sales
Net income (loss):
Net income (loss) - GAAP
Loss on sale of Argentina subsidiary (8)
Accrued social insurance adjustment (9)
Reversal of accounts receivable reserve (10)
Income tax provision on adjustments
Other income tax adjustments (11)
Adjusted Non-GAAP net income
Diluted shares used in computing earnings per share:
Adjusted Non-GAAP
Diluted earnings (loss) per share:
Diluted earnings (loss) per share - GAAP
Adjusted Non-GAAP diluted earnings per share
The twelve months ended December 31, 2020 includes costs directly attributable to the additional Section 301 U.S. tariffs implemented in 2018 on goods manufactured in China and imported into the U.S.
The three and twelve months ended December 31, 2021 and 2020 include excess manufacturing overhead costs due to the expansion of our manufacturing facility in Mexico where products destined for the U.S. market are now manufactured. These products destined for the U.S. market were previously manufactured in China. Additionally, the twelve months ended December 31, 2020 includes excess manufacturing overhead costs incurred as we temporarily shut-down our China and Mexico-based factories as a result of the COVID-19 pandemic.
Consists of impairment charges related to lower utilization of fixed assets in our China-based factories as a result of our long-term factory planning strategy of reducing our concentration risk in that region.
Consists of the loss recorded on the sale of our Ohio call center in February 2020.
Consists of the gain associated with the January 2021 release from our guarantee of the lease obligation related to our Ohio call center which was sold in February 2020.
Consists of depreciation related to the mark-up from cost to fair value of fixed assets acquired in business combinations.
Consists of expenses related to our various litigation matters involving Roku, Inc. and certain other related entities including two Federal District Court cases, two International Trade Commission investigations and the defense of various inter partes reviews before the US Patent and Trademark Board.
Consists of the loss recorded on the sale of our Argentina subsidiary in September 2021.
Consists of the reversal of a social insurance accrual related to our Guangzhou entity, which was sold in 2018. The indemnification agreement related to the sale of our Guangzhou entity expired in the second quarter of 2020.
Consists of the reversal of a reserve on an accounts receivable balance related to our Guangzhou entity, which was sold in 2018. The amount was recovered during the fourth quarter of 2020.
The twelve months ended December 31, 2020 includes the reversal of a reserve of an uncertain tax position related to our Guangzhou entity, which was sold in 2018. The indemnification agreement related to the sale of our Guangzhou entity expired in the second quarter of 2020.
Paul Arling, Chairman & CEO, UEI, 480.530.3000
Investors: Kirsten Chapman, LHA Investor Relations, uei@lhai.com, 415.433.3777

redpajama_set_name: RedPajamaCommonCrawl


text:
4.6 magnitude earthquake 105 km from Al Ḩudaydah, Muḩāfaz̧at al Ḩudaydah, Yemen
UTC time: Friday, April 29, 2011 16:41 PM
Magnitude Type: mb
USGS page: M 4.6 - near the west coast of Yemen
2011-04-29 16:41:32 UTC 4.6 magnitude, 9 km depth
Al Ḩudaydah, Muḩāfaz̧at al Ḩudaydah, Yemen
April 29, 2011 UTC
Epicenter at 15.094, 42.027
105.2 km from Al Ḩudaydah (65.2 miles)
Near The West Coast Of Yemen
Depth: 9 km
98.2 km from Al Ḩudaydah (61.2 miles)
Epicenter at 15.044, 42.14
This earthquake is on the map of The Middle East and is close to:
Near The Coast Of Eritrea
Eritrea Ethiopia
Eritrea Ethiopia Border
Yemen Saudi Arabia Border
Golfe De Tadjoura, Djibouti
Near The Coast Of Djibouti
Northwestern Somalia
Near The Coast Of Yemen
Western Saudi Arabia


text:
Elon prepares for Wake Forest
Thursday night kickoff leads to adjustment in calendar for Skrosky, Phoenix
By Alex Simon | 9/2/15 5:03pm
Welcome to Friday.
No, you're not reading that wrong.
According to Rich Skrosky, head coach for the Elon University football team, the mindset going into the Thursday night season opener against Wake Forest University makes Thursday a Saturday.
"In post-practice, we talk a lot about how tomorrow is, to a lot of people, Sunday," Skrosky said after Saturday's practice. "But in Wake's world, and Elon's world, it is Tuesday."
The day of the week means a lot for this game, which is the first midweek game for the Phoenix since 1995, when West Georgia came to Burlington and beat Elon 35-16.
For Skrosky, midweek games are nothing new – he spent three years in the Mid-American Conference (MAC) as the offensive coordinator for Ball State University. MAC teams often play games on Tuesdays and Wednesdays in November, and the Cardinals had five such games during his time there.
"One of the benefits about going to Ball State is knowing how to deal with the midweek games," Skrosky said. "Now we can get the team to understand how that, yeah, it is Sunday, but it is a workday, like a Tuesday."
The game in Winston-Salem is Thursday, which makes the message in the football program clear: Today is Friday. Get ready for a Saturday night kickoff.
Series history
This game will be the 11th matchup for the schools, with Wake Forest holding the 9-0-1 edge. But, Elon will travel I-40 to Winston-Salem to take on the Demon Deacons for just the second time in school history.
The two schools faced each other eight times in the 1920s, with seven in the town of Wake Forest. The Demon Deacons won seven of the eight matchups. The eighth was a 0-0 tie in 1927.
The last time these two schools met before World War II was in 1939, with Wake Forest shutting out Elon 34-0 in a neutral site game in Greensboro. After the 1939 matchup, they would not converge on the football field again for 70 years.
When the football programs finally reacquainted in Winston-Salem in 2009, Wake Forest emerged victorious, 35-7. Skrosky was the offensive coordinator for Elon at the time.
Player to watch: defensive tackle Marquise Wright
Entering his final season of collegiate eligibility, Wright is one of the only players at Elon who has played in games at the Football Bowl Subdivision (FBS) level, because he transferred to Elon after only playing in two games in three years at Rutgers University.
"The biggest stadium I've ever played in was at the University of Arkansas in Fayetteville, Arkansas," Wright said, recalling his previous university's Sept. 22, 2012 victory over the Razorbacks in front of 72,543 people.
For many of the Elon players, especially the freshmen, playing in front of a large crowd in an Atlantic Coast Conference stadium would be their largest audience ever. It is on upperclassmen and FBS transfers to try to prepare their younger teammates for the environment. Wright is both, and understands the perspective he provides.
"They [the underclassmen] need to understand the stadium or crowd doesn't really mean much," Wright said. "At the end of the day, we run those one-tens by ourselves. We wake up at 6 a.m. by ourselves.
"I told them to focus on blocking the noise out and just go play ball, and just keep doing what we've been doing all camp."
Similar situations
Though Wake Forest seems to have a set quarterback, Skrosky says he feels the Phoenix and Demon Deacons are extremely similar. Sophomore John Wolford is the returning starter, but freshman Kendall Hinton took snaps with the second team in the spring game.
"[Wake Forest] has an incumbent from last year," Skrosky said. "But everything you've heard – and I guess, with us being 50 miles away, I know the kid from Southern Durham and I know what that staff thinks of him – let's just put it this way: I'm not going to be shocked to see him on Thursday."
Beyond the quarterback position, Elon and Wake Forest are similar in the way the rosters are constructed.
"When you look at their depth chart, they have more freshman on it than we do, especially on the offensive side of the ball," Skrosky said. "There's a lot of familiarity with the staff, and I think you're going to see a lot of young guys [playing for] Wake."
The QB conundrum
With kickoff happening tomorrow, there is still no decision as to who will start at quarterback for Phoenix.
"It's obvious that neither one of those guys has totally separated themselves," Skrosky said. "Otherwise we would have named a guy already. As I've told everybody, I couldn't think of two better kids to have represent this program than Connor [Christiansen] and Daniel [Thompson]."
The decision time is still to be determined, and Skrosky acknowledged that there could be an element of gamesmanship to it.
"It might be after Tuesday's practice, and then, if it's that late, we might go right up to game time with it," Skrosky said. He also said that the media "might ask me, 'Is it out of the question that both of them will play?' They might. They truly might. They're not completely different guys, but there are some characteristics that Connor has that Daniel doesn't and vice versa."
For junior running back B.J. Bennett, who will be a team captain for the game, the two quarterbacks have more similarities than people would assume.
"They're both instinctual. They make plays that I didn't think they were going to do," Bennett said. "They make those plays naturally, and they both are good leaders."
As a running back with experience, Elon will be counting on Bennett to help the new starting quarterback's transition to collegiate football.
"They both can play, so I'm ready with whoever they put out," Bennett said. "I know they will lead the team."
Skrosky hasn't lost sight of the humor in the lead-up to the game, especially when it comes to naming his quarterback.
"Well, somebody has to walk out for the first play," Skrosky said. "I guess we're going to name one by then."


text:
Margistrombus marginatus, common name: the Marginate Conch,  is a species of sea snail, a marine gastropod mollusk in the family Strombidae, the true conchs.

Subspecies
 Margistrombus marginatus sowerbyorum Visser & Man In't Veld, 2005
 Margistrombus marginatus succincta (Linnaeus, 1758)

Description
The shell size varies between 40 mm and 75 mm.

Distribution
This species occurs in the Andaman Sea, at the southern tip of India and the Strait of Malacca.

References

External links

Strombidae
Gastropods described in 1758
Taxa named by Carl Linnaeus


text:
From policy to practice: exploring practitioners' perspectives on social enterprise policy claims
Micaela Mazzei, Michael J. Roy
While there has been significant academic focus on social enterprise policy for a number of years now, the links between policy and the practice of social enterprise have received comparatively less attention. Scotland is recognised as having a particularly supportive environment for social enterprise; the Scottish Government has publicly endorsed social enterprise and made considerable investment into the sector. Based upon an in-depth qualitative analysis of the perceptions of social enterprise practitioners and stakeholders across Scotland, we explore whether the rhetoric of support matches practitioners experience of 'doing' social enterprise. Reviewing emerging issues and reflecting upon the complex nature of the Scottish context, including in relation to welfare reform, we find that in contrast to the claims of politicians, the attitude of local authorities in Scotland, coupled with a lack of understanding of the needs and requirements of social enterprise at the local authority level, has led to a rather more 'patchwork' picture than the rhetoric would seem to suggest. While some local authorities recognise the potential of social enterprise for their local economies and privilege and encourage cooperation, others are less inclined to openly support social enterprise, particularly those that are small in scale. Underpinning these contentions, we argue, are unrealistic expectations about the prospects of social enterprises being able to become 'sustainable', and how this could be achieved.
Voluntas
Mazzei, M. & Roy, M.J. (2017) Voluntas article
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Final published version, 481 KBLicence: CC BY
Fingerprint Dive into the research topics of 'From policy to practice: exploring practitioners' perspectives on social enterprise policy claims'. Together they form a unique fingerprint.
rhetoric Social Sciences
local economy Social Sciences
privilege Social Sciences
politician Social Sciences
Mazzei, M., & Roy, M. J. (2017). From policy to practice: exploring practitioners' perspectives on social enterprise policy claims. Voluntas. https://doi.org/10.1007/s11266-017-9856-y
Mazzei, Micaela ; Roy, Michael J. / From policy to practice: exploring practitioners' perspectives on social enterprise policy claims. In: Voluntas. 2017.
@article{f5dba4b3e94a4963bf85fe8994d4d3a4,
title = "From policy to practice: exploring practitioners' perspectives on social enterprise policy claims",
abstract = "While there has been significant academic focus on social enterprise policy for a number of years now, the links between policy and the practice of social enterprise have received comparatively less attention. Scotland is recognised as having a particularly supportive environment for social enterprise; the Scottish Government has publicly endorsed social enterprise and made considerable investment into the sector. Based upon an in-depth qualitative analysis of the perceptions of social enterprise practitioners and stakeholders across Scotland, we explore whether the rhetoric of support matches practitioners experience of {\textquoteleft}doing{\textquoteright} social enterprise. Reviewing emerging issues and reflecting upon the complex nature of the Scottish context, including in relation to welfare reform, we find that in contrast to the claims of politicians, the attitude of local authorities in Scotland, coupled with a lack of understanding of the needs and requirements of social enterprise at the local authority level, has led to a rather more {\textquoteleft}patchwork{\textquoteright} picture than the rhetoric would seem to suggest. While some local authorities recognise the potential of social enterprise for their local economies and privilege and encourage cooperation, others are less inclined to openly support social enterprise, particularly those that are small in scale. Underpinning these contentions, we argue, are unrealistic expectations about the prospects of social enterprises being able to become {\textquoteleft}sustainable{\textquoteright}, and how this could be achieved.",
keywords = "social enterprise, policy and practice, Scotland",
author = "Micaela Mazzei and Roy, {Michael J.}",
note = "Requested acceptance email 21-3-17 Author confirmed funding is FP7 13-3-17 Acknowledgements: The research underpinning this paper was part of the EFESEIIS (Enabling the Flourishing and the Evolution of Social Entrepreneurship for Inclusive and Innovative Societies) project funded by the European Union{\textquoteright}s Seventh Framework Programme for research, technological development and demonstration under Grant Agreement No 613179. ",
doi = "10.1007/s11266-017-9856-y",
journal = "Voluntas",
publisher = "Universidade Federal de Santa Maria (UFSM)",
Mazzei, M & Roy, MJ 2017, 'From policy to practice: exploring practitioners' perspectives on social enterprise policy claims', Voluntas. https://doi.org/10.1007/s11266-017-9856-y
From policy to practice: exploring practitioners' perspectives on social enterprise policy claims. / Mazzei, Micaela; Roy, Michael J.
In: Voluntas, 03.2017.
T1 - From policy to practice: exploring practitioners' perspectives on social enterprise policy claims
AU - Mazzei, Micaela
AU - Roy, Michael J.
N1 - Requested acceptance email 21-3-17 Author confirmed funding is FP7 13-3-17 Acknowledgements: The research underpinning this paper was part of the EFESEIIS (Enabling the Flourishing and the Evolution of Social Entrepreneurship for Inclusive and Innovative Societies) project funded by the European Union's Seventh Framework Programme for research, technological development and demonstration under Grant Agreement No 613179.
N2 - While there has been significant academic focus on social enterprise policy for a number of years now, the links between policy and the practice of social enterprise have received comparatively less attention. Scotland is recognised as having a particularly supportive environment for social enterprise; the Scottish Government has publicly endorsed social enterprise and made considerable investment into the sector. Based upon an in-depth qualitative analysis of the perceptions of social enterprise practitioners and stakeholders across Scotland, we explore whether the rhetoric of support matches practitioners experience of 'doing' social enterprise. Reviewing emerging issues and reflecting upon the complex nature of the Scottish context, including in relation to welfare reform, we find that in contrast to the claims of politicians, the attitude of local authorities in Scotland, coupled with a lack of understanding of the needs and requirements of social enterprise at the local authority level, has led to a rather more 'patchwork' picture than the rhetoric would seem to suggest. While some local authorities recognise the potential of social enterprise for their local economies and privilege and encourage cooperation, others are less inclined to openly support social enterprise, particularly those that are small in scale. Underpinning these contentions, we argue, are unrealistic expectations about the prospects of social enterprises being able to become 'sustainable', and how this could be achieved.
AB - While there has been significant academic focus on social enterprise policy for a number of years now, the links between policy and the practice of social enterprise have received comparatively less attention. Scotland is recognised as having a particularly supportive environment for social enterprise; the Scottish Government has publicly endorsed social enterprise and made considerable investment into the sector. Based upon an in-depth qualitative analysis of the perceptions of social enterprise practitioners and stakeholders across Scotland, we explore whether the rhetoric of support matches practitioners experience of 'doing' social enterprise. Reviewing emerging issues and reflecting upon the complex nature of the Scottish context, including in relation to welfare reform, we find that in contrast to the claims of politicians, the attitude of local authorities in Scotland, coupled with a lack of understanding of the needs and requirements of social enterprise at the local authority level, has led to a rather more 'patchwork' picture than the rhetoric would seem to suggest. While some local authorities recognise the potential of social enterprise for their local economies and privilege and encourage cooperation, others are less inclined to openly support social enterprise, particularly those that are small in scale. Underpinning these contentions, we argue, are unrealistic expectations about the prospects of social enterprises being able to become 'sustainable', and how this could be achieved.
KW - social enterprise
KW - policy and practice
KW - Scotland
U2 - 10.1007/s11266-017-9856-y
DO - 10.1007/s11266-017-9856-y
JO - Voluntas
JF - Voluntas
Mazzei M, Roy MJ. From policy to practice: exploring practitioners' perspectives on social enterprise policy claims. Voluntas. 2017 Mar. https://doi.org/10.1007/s11266-017-9856-y


text:
Research ArticleNEUROPHARMACOLOGY
Elevation of Endocannabinoid Levels in the Ventrolateral Periaqueductal Grey through Inhibition of Fatty Acid Amide Hydrolase Affects Descending Nociceptive Pathways via Both Cannabinoid Receptor Type 1 and Transient Receptor Potential Vanilloid Type-1 Receptors
Sabatino Maione, Tiziana Bisogno, Vito de Novellis, Enza Palazzo, Luigia Cristino, Marta Valenti, Stefania Petrosino, Vittorio Guglielmotti, Francesco Rossi and Vincenzo Di Marzo
Journal of Pharmacology and Experimental Therapeutics March 2006, 316 (3) 969-982; DOI: https://doi.org/10.1124/jpet.105.093286
Sabatino Maione
Department of Experimental Medicine, Section of Pharmacology "L. Donatelli," Second University of Naples, Naples, Italy (S.M., V.d.N., E.P., F.R.); Endocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Pozzuoli (Napoli), Italy (T.B., M.V., S.P., V.D.M.); and Endocannabinoid Research Group, Institute of Cybernetics "E. Caianiello" Consiglio Nazionale delle Ricerche, Pozzuoli (Napoli), Italy (L.C., V.G.)
Tiziana Bisogno
Vito de Novellis
Enza Palazzo
Luigia Cristino
Marta Valenti
Stefania Petrosino
Vittorio Guglielmotti
Vincenzo Di Marzo
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.
You are going to email the following Elevation of Endocannabinoid Levels in the Ventrolateral Periaqueductal Grey through Inhibition of Fatty Acid Amide Hydrolase Affects Descending Nociceptive Pathways via Both Cannabinoid Receptor Type 1 and Transient Receptor Potential Vanilloid Type-1 R…
Message Subject (Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
Message Body (Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
Journal of Pharmacology and Experimental Therapeutics March 1, 2006, 316 (3) 969-982; DOI: https://doi.org/10.1124/jpet.105.093286
Detailed in vitro pharmacological characterization of the clinically viable NOP receptor antagonist BTRX-246040
Dorsoventral-specific effects of a sarin surrogate, diisopropylfluorophosphate, on synaptic transmission in the mouse hippocampus
Genome-wide siRNA screening reveals a role for Cullin3-RING ligase signaling in heterologous sensitization of adenylyl cyclase
Show more Neuropharmacology


After you might have lived in a house for a lot of years you start to get a bit uninterested in the present layout and decide to refurbish the place. Likewise, an uneven or inadequately laid tilework will end up costing you money and time. Because a kitchen gives a barely larger return on investment than a toilet, it could be clever to start with a mission in the kitchen. Two of the largest bills concerned in this technique are stamp duty and selling agent commissions , which may add hundreds of dollars to the full prices of the challenge.
Costs, promotions, styles, and availability could differ. These elements are just like these you would possibly use to determine which enterprise to pick out from an area Yellow Pages listing, together with proximity to where you might be searching, experience within the particular providers or merchandise you want, and comprehensive business information to help consider a enterprise's suitability for you.
The Company offers in-warranty and out-of-guarantee repair providers for appliances, outside power gear, instruments, grills, fireplaces and water heaters by means of its stores or within the home by means of its Authorized Service Restore Network.
On January eight, 2018, we returned the objects to the Lowes Retailer and as an alternative of placing the quantities again onto the credit card, Lowes gave our contractor retailer credits in his title, which was not authorized by Rahul Khanna or Geeta Khanna, the purchasers and the cardholders.


text:
Experimental Models for Vascular Endothelial Dysfunction
Pitchai Balakumar, Seema Jindal , Dhvanit Indravadan Shah and Manjeet Singh
The endothelium is recognized as a physical barrier between blood and vascular wall. It regulates vascular tone, endothelial permeability and vascular growth. Dysfunction of endothelium has been characterized by partial or complete loss of balance between vasorelaxation and vasoconstriction, thrombosis and thrombolysis. Various experimental evidences have shown that endothelial dysfunction mainly occurs due to reduced nitric oxide production and increased oxidative stress. Vascular endothelial dysfunction is associated with pathogenesis of atherosclerosis, hypertension, diabetes mellitus, coronary artery diseases and stroke. In the present review, we have discussed various recently developed animal models for vascular endothelial dysfunction, which may open new vista to develop agents for improving vascular endothelial function.
Related Articles in ASCI
Similar Articles in this Journal
Report Citation
Science Alert
Pitchai Balakumar, Seema Jindal , Dhvanit Indravadan Shah and Manjeet Singh , 2007. Experimental Models for Vascular Endothelial Dysfunction. Trends in Medical Research, 2: 12-20.
DOI: 10.3923/tmr.2007.12.20
URL: https://scialert.net/abstract/?doi=tmr.2007.12.20
Endothelium forms an innermost lining of blood vessels (Lusher and Barton, 1997; Endmann and Schiffrin, 2004). Vascular endothelium has anticoagulant and antithrombotic activites in order to ensure free flow of blood through arteries (Bombeli et al., 1997). It regulates various mediators including nitric oxide (NO), prostanoids, endothelin-1 (ET-1), angiotensin-II (Ang-II), tissue plasminogen activator (tPA), von willbrand factor (vWF), adhesion molecules and cytokines (Quyyumi, 1998; Schalkwijk and Stehouwer, 2005). NO, is also known as endothelium derived relaxing factor (EDRF), which is synthesized from L-arginine by endothelial nitric oxide synthase (eNOS) in endothelium. NO plays a crucial role in regulating wide spectrum of cardiovascular functions such as mediating vasorelaxation, inhibiting leukocytes-endothelial adhesion and preventing platelet aggregation (Kawashima, 2004; Yang and Ming, 2006). Endothelial dysfunction has been characterized by partial or complete loss of balance between vasorelaxation and vasoconstriction (Vane et al., 1990; Masaki, 1995) and thrombosis and thrombolysis (Danon and Skutelsky, 1976). Experimental and clinical evidences suggest that endothelial dysfunction leads to reduced endothelial NO production (Bugiardini et al., 2004; Lerman and Zeiher, 2005). Vascular endothelial dysfunction has been associated with various disorders such as hypertension (Sainani and Maru, 2004), coronary artery diseases (Caramori and Zago, 2000), diabetes mellitus (De Vriese et al., 2000; Nakagami et al., 2005), atherosclerosis (Spieker et al., 2001; Bonetti et al., 2003) and stroke (Cosentino et al., 2001; Faraci and Lentz, 2004). However, the literature for animal models for vascular endothelial dysfunction is inadequately available. The current review has focused on various experimental models to produce vascular endothelial dysfunction.
Fig. 1: Pharmacological mechanisms involving in the pathogenesis of vascular endothelial dysfunction. HFD indicates high fat diet, STZ indicates streptozotocin, DOCA indicates deoxycortisone acetate, TAB indicates transverse aortic banding, LPS indicates lipopolysaccharide, eNOS indicates endothelial nitric oxide synthase and ROS indicates reactive oxygen species
Experimental Models to Induce Vascular Endothelial Dysfunction
The animal models for vascular endothelial dysfunction share many features which are universal to human endothelial dysfunction and have been depicted by targeting eNOS, xanthine oxidase and NADH/NADPH oxidase pathways (Fig. 1).
Hypertension-induced Vascular Endothelial Dysfunction
Endothelium plays an important role in regulation of blood pressure (Taddei et al., 2001). Hypertension has been shown to cause vascular endothelial dysfunction (Sainani and Maru, 2004). The method commonly used to induce hypertension in rats is goldblatt techniques such as 2-kidney 1-clip model and 1-kidney 1-clip model, which have been demonstrated to increase arterial blood pressure, total peripheral resistance (TPR) and decrease endothelium dependent relaxation to acetylcholine (Ach) (Share et al., 1982; Sventek et al., 1996). Recently we have shown that uninephrectomy followed by administration of DOCA salt (40 mg kg-1, s.c.) in olive oil along with 1% NaCl and 0.5% KCl twice weekly for 6 weeks has produced vascular endothelial dysfunction (Shah and Singh, 2006a). Further, treatment with L-NAME (eNOS inhibitor) (50 mg kg-1 day-1) for 6 weeks has been shown to increase blood pressure and reduce endothelium dependent relaxation in rats (Kung et al., 1995). Infusion of angiotensin-II (0.7 mg kg-1 day-1) for 5 days has been noted to increase systolic blood pressure, generation of superoxide anion and cause impairment of Ach-induced relaxation (Rajagopalan et al., 1996). Moreover, chronic administration of ethinyl estradiol (1.5 mg kg-1 day-1) for 3 weeks has been shown to increase blood pressure and consequently reduce endothelium dependent relaxation (Thakre et al., 2000). Furthermore moderately high fat diet administration for 10 weeks has been shown to develop vascular endothelial dysfunction in rats characterized by hypertension, increase in reactive oxygen species (ROS) and lipid peroxidation (Dobrian et al., 2001). Rats treated with single injection of monocrotaline (40 mg kg-1 or 100 mg kg-1) has increased mean pulmonary arterial pressure, ventricular hypertrophy and produced injury to endothelium of pulmonary artery (Gout et al., 1999; Leung et al., 2003). Spontaneously Hypertensive Rats (SHR) show cardiovascular responsiveness such as increase in blood pressure, total peripheral resistance and intravascular volume due to fluid retention and have been demonstrated to decrease endothelium dependent relaxation (Sunano et al., 1989).
Diabetes-induced Vascular Endothelial Dysfunction
Diabetes is characterized by hyperglycemia which is an independent risk factor for the development of cardiovascular diseases (Nakagami et al., 2005). Endothelial dysfunction plays an important role in pathogenesis of diabetic vascular diseases. Several mechanisms have been reported in diabetes-induced impairment of endothelium dependent relaxation including impaired signal transduction availability and impaired release of EDRF (De Vriese et al., 2000). Recently, from our laboratory, it has been shown that administration of streptozotocin (55 mg kg-1, i.p. once) in rats produced diabetes and consequently induced vascular endothelial dysfunction (Shah and Singh, 2006b-d).
Hyperhomocysteinemia-induced Vascular Endothelial Dysfunction
One of the most consistent finding observed in the studies of experimental hyperhomocysteinemia is impairment of NO mediated vasodilation (Lentz et al., 2003). Hyperhomocysteinemia-induced increase in reactive oxygen species may lead to oxidative inactivation of endothelium derived NO (Eberhardt et al., 2000). Further, hyperhomocysteinemia has been shown to elevate asymmetric dimethyl arginine (ADMA) which is an endogenous eNOS inhibitor (Cooke, 2000). Recently, we have shown that hyperhomocysteinemia-induced endothelial dysfunction in rats can be produced by administration of L-methionine (1.7%W/W, p.o., daily) suspension in 0.1% CMC for four weeks (Shah and Singh, 2006b-d).
High Fat Diet-induced Vascular Endothelial Dysfunction
Recently, our laboratory has shown that high fat diet in composition of 5% w/w cholesterol, 10% w/w lard fat, 0.1% w/w sodium cholate and 1% w/w coconut oil mixed with standard chow diet has produced vascular endothelial dysfunction (Shah and Singh, 2006a). Combination of methionine (1%) and cholesterol (0.5%) diet has been noted to abolish endothelium dependent relaxation in rabbits (Zulli et al., 2003). High fat diet comprising of pig chow supplemented with 2% cholesterol, 17.1% coconut oil, 20.3% corn oil and 0.7% sodium cholate has been reported to decrease endothelium dependent relaxation and eNOS level in pigs (Henderson et al., 2004).
Hyperuricemia-induced Vascular Endothelial Dysfunction
It has been suggested that uric acid may induce vascular endothelial dysfunction by inhibiting endothelial NO production and increasing ROS level (Kanellis and Kang, 2005). Mild hyperuricemia can be induced by administrating oxonic acid (750 mg kg-1 day-1, p.o.) in rats (Khosla et al., 2005). Further, hyperuricemia is induced by administration of yeast extract paste (20-30 mg kg-1 day-1) for 7 days in rats and mice. Yeast would disturb normal purine metabolism by increasing xanthine oxidase activity and generating large quantities of uric acid with ROS and this model has been shown to be similar to human hyperuricemia (Chen et al., 2006).
Heart Failure-induced Vascular Endothelial Dysfunction
Endothelial dysfunction is a newly discovered hallmark of heart failure which is characterized by decreased release of EDRF in vasculature and increased generation of oxygen free radicals. Vascular endothelial dysfunction is induced by left coronary artery ligation model of heart failure in rats (Indik et al., 2001). Partial aortic constriction has been shown to produce pressure overload and consequently ventricular hypertrophy (Balakumar and Singh, 2005, 2006a, b, c). Pressure overloaded ventricular hypertrophy was induced in guinea pig by placing a hemoclip of 0.5 mm in diameter around a sub diaphragmatic aorta just above the renal arteries (Lang et al., 2000; Bell et al., 2001) which has been shown to increase oxidative stress and consequently produce vascular endothelial dysfunction. Further transverse aortic banding (TAB) for 2 to 11 weeks is employed to produce vascular endothelial dysfunction in mice (Ogita et al., 2004).
Oestrogen Deficiency-induced Vascular Endothelial Dysfunction
Oestrogen regulates the endothelial nitric oxide synthase activity either genomically by modulating its expression (Levin, 2005) or nongenomically by regulating its activity (Chambliss et al., 2002). The incidence of cardiovascular disorders such as hypertension, atherosclerosis and coronary artery disease are noted to increase in oestrogen deficiency associated with menopause. The endothelial dysfunction as a result of menopause is characterized by increase in plaque formation and intimal thickening (Squadrito et al., 2000; Beral et al., 2002). Surgical oestrogen deficiency by ovariectomy impairs Ach-induced endothelium dependent relaxation (Walker et al., 2001). To induce endothelial dysfunction by ovariectomy, rats were anaesthetized with chloral hydrate (250 mg kg-1 i.p.) and incision was made in right and left dorsal side of flanks. Ovaries along with uterus were pulled out and suture was applied at the end of uterus and beginning of ovary. The ovaries on both sides were removed. The uteri on both sides were pushed back and incisions were sutured in layers. Neosporin antibiotic powder was applied on wounds and animals were allowed for 4 weeks to produce vascular endothelial dysfunction.
Nicotine-induced Vascular Endothelial Dysfunction
Cigarette smoking is a strong risk factor for vascular diseases and known to cause dysfunction of endothelium (Zhang et al., 2006). Nicotine contributes to smoking-induced endothelial dysfunction because of its ability to impair endothelium dependent vasorelaxation. Administration of nicotine (2 mg kg-1 day-1 i.p.) for 4 weeks has been shown to decrease bradykinin mediated endothelium dependent vasodilation in rats (Paganelli et al., 2001; Luo et al., 2006).
Endotoxic Shock-induced Vascular Endothelial Dysfunction
Endothelial dysfunction plays a crucial role in pathophysiology of septic shock due to gram-negative bacteria (Cotran and Pober, 1990). Endothelium derived NO production has been noted to be reduced during endotoxemia (Young et al., 1991; Myers et al., 1995). A single injection of endotoxin (E. coli) (15 mg kg-1 i.v.) has been shown to produce vascular endothelial dysfunction in rats within 6 h. Further, in a rabbit model of endotoxic shock, a single lipopolysaccharide (LPS) bolus (0.5 mg kg-1 i.v.). Escherichia coli endotoxin) has produced vascular endothelial dysfunction in about 5 days (Wiel et al., 2000).
Arsenic-induced Vascular Endothelial Dysfunction
Arsenic, a ubiquitous element distributed in the environment and contaminated drinking water is the main source of arsenic (Abernathy et al., 1999). Arsenic has been suggested to inhibit eNOS and produce excessive ROS which contributes to endothelial dysfunction. Chronic arsenic exposure has been associated with diabetes, cardiovascular diseases (Rossman, 2003; Tseng, 2004) and cerebrovascular disorders (Wang et al., 2002; Simeonova et al., 2003). Continuous administration of arsenate (5 mg L-1) in drinking water for 18 weeks has been shown to produce vascular endothelial dysfunction in rabits (Kumagi and Pi, 2004).
Glutathione Peroxidase Deficiency-induced Vascular Endothelial Dysfunction
Glutathione peroxidase (GPx–1) is an antioxidant enzyme plays an important role in protection of cells against oxidative stress (Raes et al., 1987). GPx-1 deficiency directly induces an increase in vascular oxidative stress and decrease in eNOS mediated NO bioavailability (Schachinger et al., 2000; O'Donnell and Freeman, 2001). Glutathione peroxidase deficiency-induced vascular endothelial dysfunction is shown in murine model of homozygous deficiency of GPx-1 (GPx-1-1). Mesentric artery of GPx-1-1 mice demonstrated paradoxical vasoconstriction to β-methacholine and bradykinin where as wild type (WT) mice showed dose-dependent vasodilation in response to both agonists (Forgione et al., 2002).
Hypochlorite-induced Vascular Endothelial Dysfunction
It has been suggested that blood vessels exposed to hypochlorite (HoCl) exhibit a defect in endothelium derived NO bioavailability manifested as impaired endothelium dependent arterial relaxation (Stocker et al., 2004). HoCl-induced vascular endothelial dysfunction may be due to reduction in NO production by decreasing eNOS level and increasing ROS production (Nuszkouski et al., 2001; Stocker et al., 2004). Pretreatment with HoCl (400 μM) for 2 h has been shown to produce impaired Ach-induced relaxation in rabit aortic ring preparation (Witting et al., 2005).
Excessive Glucocorticoid-induced Vascular Endothelial Dysfunction
Glucocorticoids (GC) have been used widely for the treatment of patients with various disorders including autoimmune disorders. GC such as prednisolone, methylprednisolone and dexamethasone are often limited by several adverse reactions associated with vascular system such as coronary artery diseases, hypertension and atherosclerosis (Ross and Linch, 1982; Saruta, 1996). Various clinical findings suggest that excessive GC causes overproduction of ROS and reduction of NO availability leading to vascular endothelial dysfunction in human subjects (Iuchi et al., 2003). However this has not been well demonstrated in suitable animal models.
Hypertension, diabetes, hyperhomocysteinemia and hypercholesterolemia-induced vascular endothelial dysfunction are the commonly used experimental models since these models are reflecting clinical similitude of vascular endothelial dysfunction. Developing new models employing recent advances in pathophysiology of vascular endothelial dysfunction can accelerate research in developing novel therapeutic agents to improve vascular endothelial function.
Abernathy, C.O., Y.P. Liu, D. Longfellow, H.V. Aposhian and B. Beck et al., 1999. Arsenic health effects, mechanisms of actions and research issues. Environ. Health Perspect., 107: 593-597.
CrossRef |
Balakumar, P. and M. Singh, 2005. The possible role of TNF-α in physiological and pathophysiological cardiac hypertrophy in rats. Ira. J. Pharmacol. Ther., 4: 138-142.
Direct Link |
Balakumar, P. and M. Singh, 2006. Differential role of Rho-kinase in pathological and physiological cardiac hypertrophy in rats. Pharmacology, 78: 91-97.
CrossRef | Direct Link |
Balakumar, P. and M. Singh, 2006. Effect of 3-Aminobenzamide, an inhibitor of poly (ADP-ribose) polymerase in experimental cardiac hypertrophy. Int. J. Pharmacol., 2: 543-548.
Balakumar, P. and M. Singh, 2006. The possible role of caspase-3 in pathological and physiological cardiac hypertrophy in Rats. Basic Clin. Pharmacol. Toxicol., 99: 418-424 (In Press).
PubMed | Direct Link |
Bell, J.P., S.I. Mosfer, D. Lang, F. Donaldson and M.J. Lewis, 2001. Vitamin C and quinapril abrogate LVH and endothelial dysfunction in aortic-banded guinea pigs. Am. J. Physiol. Heart Circ. Physiol., 281: H1704-H1710.
Beral, V., E. Banks and G. Reeves, 2002. Evidence from randomised trials on the long-term effects hormone replacement therapy. Lancet, 360: 942-944.
Bombeli, T., M. Mueller and A. Haeberli, 1997. Anticoagulant properties of the vascular endothelium. Thromb. Haemost., 77: 408-423.
Bonetti, P.O., L.O. Lerman and A. Lerman, 2003. Endothelial dysfunction: A marker of atherosclerotic risk. Arterioscler. Throm. Vasc. Biol., 23: 168-175.
Bugiardini, R., O. Manfrini, C. Pizzi, F. Fontana and G. Morgagni, 2004. Endothelial function predicts future development of coronary artery disease: A study of woman with chest pain and normal coronary angiograms. Circulation, 109: 2518-2523.
Caramori, P.R.A. and A.J. Zago, 2000. Endothelial dysfunction and coronary artery disease. Arq. Bras. Cardiol., 75: 173-182.
Chambliss, K.L., I.S. Yuhanna, R.G. Anderson, M.E. Mendelsohn and P.W. Shaul, 2002. Estrogen receptor β has nongenomic action in caveolae. Mol. Endocrinol., 16: 938-946.
Chen, G.L., W. Wei and S.Y. Xu, 2006. Effect and mechanism of total saponin of Dioscorea on animal experimental hyperuricemia. Am. J. Chin. Med., 34: 77-85.
Cooke, J.P., 2000. Does ADMA cause endothelial dysfunction. Arterioscl. Thromb. Vasc. Biol., 20: 2032-2037.
Cosentino, F., S. Rubatta, C. Savoia, V. Venturelli, E. Pagannonne and M. Volpe, 2001. Endothelial dysfunction and stroke. J. Cardiovasc. Pharmacol., 38: S75-S78.
Cotran, R.S. and J.S. Pober, 1990. Cytokine-endothelial interaction in inflammation, immunity and vascular injury. J. Am. Soc. Nephrol., 1: 225-235.
Danon, D. and E. Skutelsky, 1976. Endothelial surface charge and its possible relationship to thrombogenesis. Ann. N. Y. Acad. Sci., 275: 47-63.
De Vriese, A.S., T.J. Verbeuren, J.V. de Voorde, N.H. Lameire and P.M. Vanhoutte, 2000. Endothelial dysfunction in diabetes. Br. J. Phamacol., 130: 963-974.
Dobrian, A.D., M.J. Davies, S.D. Schriver, T.J. Lauterio and R.L. Prewitt, 2001. Oxidative stress in a rat model of obesity induced hypertension. Hypertensive, 37: 554-560.
Eberhardt, R.T., M.A. Forgione, A. Cap, J.A. Leopold and M.A. Rudd et al., 2000. Endothelial dysfunction in a murine model of hyperhomocysteinemia. J. Clin. Invest., 106: 483-491.
Endmann, D.H. and E.L. Schiffren, 2004. Endothelial dysfunction. J. Am. Soc. Nephrol., 15: 1983-1992.
Faraci, F.M. and S.R. Lentz, 2004. Hyperhomocysteinemia, oxidative stress and cerebral vascular dysfunction. Stroke, 35: 345-347.
Forgione, M.A., N. Weiss, S. Heydrick, A. Cap and E.S. Klings et al., 2002. Cellular glutathione peroxidase deficiency and endothelial dysfunction. Am. J. Physiol. Heart Circ. Physiol., 282: H1255-H1261.
Gout, B., M.J. Quiniou, N. Khandoudi, C. Le Dantee and B. Saiag, 1999. Impaired endothelium-dependent relaxation by adrenomedullin in monocrotaline-treated rat arteries. Eur. J. Pharmacol., 380: 23-30.
Henderson, K.K., R.J. Turk, J.W.E. Rush and M.H. Laughlin, 2004. Endothelial function in coronary arterioles from pigs with early-stage coronary disease induced by high fat, high-cholesterol-diet: Effect of exercise. J. Applied Physiol., 97: 1159-1168.
Indik, J.H., S. Goldman and M.A. Gaballa, 2001. Oxidative stress contributes to vascular endothelial dysfunction in heart failure. Am. J. Physiol. Heart Circ. Physiol., 281: H1767-1770.
Iuchi, T., M. Akaike, T. Mitsui, Y. Ohshima, Y. Shintani, H. Azuma and T. Matsumoto, 2003. Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction. Circ. Res., 92: 81-87.
Kanellis, J. and D.H. Kang, 2005. Uric acid as a mediator of endothelial dysfunction, inflammation and vascular disease. Semin. Nephrol., 25: 39-42.
Kawashima, S., 2004. The two faces of endothelial nitric oxide synthase in the pathophysiology of atherosclerosis. Endothelium, 11: 99-107.
Khosla, U.M., S. Zharikov, J.L. Finch, T. Nakagawa and C. Roncal et al., 2005. Hyperuricemia induces endothelial dysfunction. Kidney Int., 67: 1739-1742.
Kumagi, Y. and J. Pi, 2004. Molecular basis for arsenic induced alteration in nitric oxide production and oxidative stress. Implication of endothelial dysfunction. Toxicol. Applied Pharmacol., 198: 450-457.
Kung, C.F., P. Moreau, H. Takase and T.F. Luscher, 1995. L-Name hypertension alters endothelial and smooth muscle function in rat aorta. Hypertensive, 26: 744-751.
Lang, D., S.I. Mosfer, Y.Y.A. Shakes, F. Donaldson and M.J. Levis, 2000. Coronary microvascular endothelial cell redox state in left ventricular hypertrophy. The role of ang II. Circ. Res., 86: 463-469.
Lentz, S.R., R.N. Rodionov and S. Dayal, 2003. Hyperhomocysteinemia, endothelial dysfunction and cardiovascular risk, the potential role of ADMA. Atherosclerosis, 4: 61-65.
Lerman, A. and A.M. Zeiher, 2005. Endothelial function: Cardiac events. Circulation, 111: 363-368.
Leung, S.W., X. Cheng, S.L. Lim and C.C. Pang, 2003. Augmented pulmonary vascular and venous constrictions to N(G)-nitro-LBarginine methyl esters in rats with monocrotaline-induced pulmonary hypertension. Pharmacology, 69: 164-170.
Levin, E.R., 2005. Integration of the extra-nuclear and nuclear actions of estrogen. Mol. Endocrinol., 19: 1951-1959.
Luo, H.L., W.J. Zang, J. Lu, X.J. Yu and Y.X. Lin, 2006. The protective effect of captopril on nicotine-induced endothelial dysfunction in rat. Basic Clin. Pharmacol. Toxicol., 99: 237-245.
Luscher, T.F. and M. Barton, 1997. Biology of the endothelium. Clin. Cardiol., 20: 3-10.
Masaki, T., 1995. Possible role of endothelin in endothelial regulation of vascular tone. Ann. Rev. Pharmacol. Toxicol., 35: 235-255.
Myers, P.R., Q. Zhong, J.J. Jones, M.A. Tanner, H.R. Adams and J.L. Parker, 1995. Release of EDRF and NO in ex vivo perfused aorta: Inhibition by in vivo E. coli endotoxemia. Am. J. Physiol. Heart Circ. Physiol., 268: H955-H961.
Nakagami, H., Y. Kaneda, T. Ogihara and R. Morishita, 2005. Endothelial dysfunction in hyperglycemia as a trigger of atherosclerosis. Curr. Diabet. Rev., 1: 59-63.
Nuszkowski, A., R. Grabner, G. Marsche, A. Unbehaun, E. Malle and R. Heller, 2001. Hypochlorite-modified low density lipoprotein inhibits nitric oxide synthesis in endothelial cells via an intracellular dislocalization of endothelial nitric-oxide synthase. J. Biol. Chem., 276: 14212-14221.
O'Donnell, V.B. and B.A. Freeman, 2001. Interactions between nitric oxide and lipid oxidation pathways implications for vascular disease. Circ. Res., 88: 12-21.
Ogita, H., K. Node, Y. Liao, F. Ishikura and S. Beppu et al., 2004. Raloxifene prevents cardiac hypertrophy and dysfunction in pressure-overload mice. Hypertensive, 43: 237-242.
Paganelli, M.O., J.E. Tanus-Santos, J.C. Toledo, J.F. Doprado, V. Calegari and H. Moreno, 2001. Acute administration of nicotine impairs the hypotensive responses to bradykinin in rats. Eur. J. Pharmacol., 413: 241-246.
Quyyumi, A.A., 1998. Endothelial function in health and disease: New insights into the genesis of cardiovascular disease. Am. J. Med., 105: 32S-39S.
Raes, M., C. Michielis and J. Ramacle, 1987. Comparative study of the enzymatic defense systems against oxygen derived free radicals: The key role of glutathione peroxidase. Free Radic. Biol. Med., 3: 3-7.
Rajagopalan, S., S. Kurts, T. Munzel, M. Tarpey, B.A. Freeman, K.K. Griendling and D.G. Harrison, 1996. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J. Clin. Invest., 97: 1916-1923.
Ross, E.J. and D.C. Linch, 1982. Cushings syndrome-killing disease discriminatory value of signs and symptoms aiding early diagnosis. Lancet, 2: 646-649.
Rossman, T.G., 2003. Mechanism of arsenic carcinogenesis: An integrated approach. Mutant. Res., 533: 37-65.
PubMed |
Sainani, G.S. and V.G. Maru, 2004. Role of endothelial cell dysfunction in essential hypertension. J. Assoc. Physicians Ind., 52: 966-969.
Saruta, T., 1996. Mechanisms of glucocorticoid-induced hypertension. Hypertens. Res., 19: 1-8.
Schachinger, V., M.B. Britten and A.M. Zeiher, 2000. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation, 101: 1899-1906.
Schalkwijk, C.G. and C.D.A. Stehouwer, 2005. Vascular complication in diabetes mellitus: The role of endothelial dysfunction. Clin. Sci., 109: 143-159.
Shah, D.I. and M. Singh, 2006. Effect of bis-maltolato-oxovanadium on experimental vascular endothelial dysfunction. Naun. Schmie. Arch. Pharmacol., 373: 221-229.
Shah, D.I. and M. Singh, 2006. Involvement of Rho-kinase in experimental vascular endothelial dysfunction. Mol. Cell. Biochem., 283: 191-199.
Shah, D.I. and M. Singh, 2006. Inhibition of protein tyrosine phosphatase improves vascular endothelial dysfunction. Vasc. Pharmacol., 44: 177-182.
Shah, D.I. and M. Singh, 2007. Possible role of Akt to improve vascular endothelial dysfunction in diabetic and hyperhomocysteinemic rats. Mol. Cell. Biochem., 295: 65-74.
Share, L., J.T. Crofton, W.J. Lee-Kwon and R.E. Shade, 1982. One clip, one-kidney hypertension in rats with hereditary hypothalamic diabtes incipidus. Clin. Exp. Hypertens., 4: 1261-1270.
Simeonova, P.P., T. Hulderman, D. Harki and M.I. Luster, 2003. Arsenic exposure accelerates atherogenesis in apolipoprotein E(-/-) mice. Environ. Health Perspect., 111: 1744-1748.
Spieker, L.E., T.F. Luscher and G. Noll, 2001. Current strategies and perspective for correcting endothelial dysfunction in atherosclerosis. J. Cardiovasc. Pharm., 38: S35-S41.
Squadrito, F., D. Altavilla, G. Squadrito, A. Saitta and D. Cucinotta et al., 2000. Genistein supplementation and estrogen replacement therapy improve endothelial dysfunction induced by ovariectomy. Cardiovasc. Res., 45: 454-462.
Stocker, R., A. Huang, E. Jeranian, J.Y. Hou, T.T. Wu and S.R. Thomal, J.F. Keaney, 2004. Hypochlorous acid impairs endothelium-derived nitric oxide bioactivity through a superoxide-dependent mechanism. Arterioscler. Thromb. Vasc. Biol., 24: 2028-2033.
Sunano, S., S. Osugi and K. Shimamura, 1989. Blood pressure and impairment of endothelium dependent relaxation in spontaneously hypertensive rats. Hypertensive, 27: 49-55.
Sventek, P., J.S. Li, K. Grove, C.F. Deschepper and E.L. Schiffrin, 1996. Vascular structure and expression of endothelial 4 gene in L-NAME-treated spontaneously hypertensive rats. Hypertensive, 27: 49-55.
Taddei, S., A. Virdis, L. Ghiadoni, I. Sudano and A. Salvetti, 2001. Endothelial dysfunction in hypertension. J. Cardiovasc. Pharm., 38: S11-S14.
Thakre, B.S., K.K. Shah and J.D. Bhatt, 2000. Study of effects on the sensitivity of vascular and extravascular tissues in ethinyl estradiol-induced hypertensive rats. Ind. J. Pharmacol., 32: 15-20.
Tseng, C.H., 2004. The potential biological mechanisms of Arsenic-induced diabetes mellitus. Toxicol. Appl. Pharmacol., 197: 67-83.
Vane, J.R., E.E. Anggard and R.M. Botting, 1990. Regulatory functions of the vascular endothelium. N. Engl. J. Med., 323: 27-36.
Walker, H.A., T.S. Dean, T.A.B. Sanders, G. Jackson, J.M. Ritter and P.J. Chowienczyk, 2001. The phytoestrogen genistein produces acute nitric oxide dependent dilation of human forearm vasculature with similar potency to 17β-estradiol. Circulation, 103: 258-262.
Wang, C.H., J.S. Jeng, P.K. Yip, C.L. Chen and L.I. Hsu et al., 2002. Biological gradient between long-term arsenic exposure and carotid atherosclerosis. Circulation, 105: 1804-1809.
Wiel, E., Q. Pu, D. Corseaux, E. Robin and R. Bordet et al., 2000. Effect of L-arginine on endothelial injury and hemostasis in rabbit endotoxin shock. J. Applied Physiol., 89: 1811-1818.
Witting, P.K., B.J. WU, M. Raftery, P. Southwell-Keely and R. Stocker, 2005. Probucol protects against hypochlorite induced endothelial dysfunction: Identification of a novel pathway of probucol oxidation to a biologically active intermediate. J. Biol. Chem., 280: 15612-15618.
Yang, Z. and X.F. Ming, 2006. Recent advances in understanding endothelial dysfunction in atherosclerosis. Clin. Med. Res., 4: 53-56.
Young, J.S., J.P. Headrick and R.M. Berne, 1991. Endothelial dependent and independent responses in the thoracic aorta during endotoxic shock. Circ. Shock., 35: 25-30.
Zhang, J.Y., Y.X. Cao, C.B. Xu and L. Edvinsson, 2006. Lipid-soluble smoke particles damage endothelial cells and reduce endothelium-dependent dilatation in rat and man. BMC Cardiovasc. Disord., 6: 3-3.
Zulli, A., R.E. Widdop, D.L. Hare, B.F. Buxton and M.J. Black, 2003. High methionine and cholesterol diet abolishes endothelial relaxation. Arterioscler. Thromb. Vasc. Biol., 23: 1358-1363.
© 2019 Science Alert. All Rights Reserved


Blender 2.7x has a built-in FBX import/export addon which can be used to export models to UE4.
You can download the latest version here, but keep in mind this tutorial is based on the FBX addon included in Blender 2.70.
In a twitch session broadcast on 3 May 2014 (http://www.twitch.tv/unrealengine/c/4174458) Lead Engine Programmer Matt Kuhlenschmidt stated that due to the need for better FBX workflow from Blender to Unreal Engine, Epic was working with the developers of the Blender FBX Export plugin to improve the already good quality.
He requested that Epic needed examples from the community of Blender models which were known to be broken when exported as FBX.
You can use any modeling technique such as Nurbs, Bezier, modifiers, etc. When you export, Blender will convert your object(s) to a mesh type. However, is recommended that you convert it inside Blender to unwrap its UVs appropriately.
Considering the nature of how the FBX exporter manages pivot points (see "Pivot Points"), working on several objects in one .blend file can cause clutter. If you are working on several objects in the same .blend file, you can store each object in a separate layer, so that they can each be placed at the center of the scene without making a mess.
See "Exporting" and "Exporting Batch" sections for more information on how to export many objects.
You only need to use one UV channel for Base Color, Roughness, Normals, and other Material related properties.
You can create your own UV map using the Mark Seams tool (Ctrl + E) and the Unwrap tool (U key), or you can make use of the automatic unwrapping functions such as Lightmap Pack or Smart UV Project. Keep in mind that the latter two will not always result in nice looking seams, which is most noticeable on organic objects.
The UV areas for all faces contained in your final FBX file should not overlap, i.e. not possess the same areas.
For Lightmass to work with your static mesh, the mesh needs a set of UV coordinates that can be used to create the lightmap.
Create a second UV channel to store the lightmap.
I recommend unwrapping the UVs for the lightmap in Blender since the automatic UV mapper inside UE4 is too slow in some cases or doesn't work at all.
Keep in mind that UV maps can't contain overlapping areas.
The FBX import/export plugin will (in most cases) place the Pivot Point of your exported objects at the origin of the world, which is at the coordinates (0, 0, 0), rather than using the Pivot Point of the objects in Blender.
This means that your objects must be positioned in such a way so that their Pivot Point is at the origin of the world, and will not be changed through exporting.
To ensure that your object is properly aligned to the World's origin (0, 0, 0), use Alt + G to clear its location.
It's better to create your materials inside UE4 instead of importing them from Blender. This will give you more control of the asset organization in your Unreal project folder. However, if your static mesh has multiple parts that will have different materials applied to them, you must assign different placeholder materials in Blender before exporting to FBX. UE4 will divide the static mesh into different elements based on the materials assigned in Blender. These will appear in UE4 as Element 0, Element 1, etc. and cannot be renamed or re-ordered. UE4 will create these elements regardless of whether or not the "Import materials" option is enabled in the FBX importer.
Open the Static Mesh Editor and use the Highlight checkboxes for each element.
Add the static mesh to a level as an actor. Then drag materials onto the desired parts of the mesh in the viewport, watching for changes to the materials in the list of elements on the right.
Give meaningful names to the materials in Blender, then make sure "Import materials" is enable when importing the FBX into UE4. This only works as long as you keep those imported materials in your UE4 project and don't change the default materials for the static mesh.
By default, when you import your static mesh asset into the Unreal Engine there will be no collision mesh associated with it. This means that players and physical objects will be able to pass through it without colliding. There are two primary methods for creating collision meshes: Automatic inside of UE4, and Custom from another 3D application.
This section still needs to be written. Full documentation on creating custom collision meshes for the FBX Content Pipeline can be found here.
This has been tested and works with Blender and the FBX export addon.
When creating custom collision geometry inside Blender, it can be very helpful to first select your model and turn on X-ray mode under the object's display mode.
In the Unreal Editor, you can automatically generate a collision mesh for your static meshes. This automatic method is not extremely accurate, but for simple props, it can get the job done. For more complex props where collision matters, it is suggested to use the above Custom Collision method to create your own collision meshes.
You will then need to click on the "Collision" menu at the top of the screen. This will present you with many options. Experiment with the different collision options to find the right fit for your model. Try the 6DOF (6 Degrees of Freedom) option first. You should see a box now appear around your mesh. If the green box does not appear, then click the green Collision button above the window to turn that layer on.
In the FBX Export menu, the value of the Scale parameter depends on how your viewport is set up in Blender. If you adjusted the Unit scale in your Scene settings, as described in the Scale Conversion: Unit Scale in Blender section, you can leave this Scale value set to 1.0.
To export only the selected objects, enable the Selected Objects check box.
You can export many models at the same time in a Batch process, but you will need to create a group for each asset or separate it by Scene in "Batch mode". You can set this configuration for a Batch export. The Batch Own Dir option is useful if you want to separate it folders. Set a name and export it.
Open it in the Static Mesh Editor and configure the collision mesh (if necessary) and any other settings such as LOD. Save it.
Insert the object into the scene.
Bake the Lightmass using the "Build" or "Build Lighting Only" command.


Decided to (very, very quickly) try out emmycic's technique of colouring using only the selection tool. Way too much fun.
One day I'll learn how to draw anything that actually resembles the character it's supposed to be. :> Cute style though. I'm gonna keep playing with this.
I'll be honest I didn't use a reference at ALL, which either makes me AMAZING or a total idiot. I couldn't even remember if Gurren characters had coloured eyes at all (apart from Nia flower-eyes).
But yay! I must draw moar.
Who is it supposed to be?
Kittan from the ever awesome Gurren Lagann.
I've never thought your art looked like Penny Arcade before. You have a very unique style, I think.
I think maybe it was the eyebrows... and the chin.
Oooh that's how I color! Using the selection tool. :D Though I don't do nearly as neat a job of it as you do.


720 Park Avenue 13A, New York, NY 10021 | Sotheby's International Realty, Inc.
Extremely rare and glamourous 12 room apartment perched high atop a most distinguished white-glove prewar cooperative. Impeccably appointed by the renowned design team of Aman Meeks, the residence was extensively featured in the firm's recent coffee table tome, The New Formal.
Distinguished by a 95 foot long planted terrace that charmingly meanders along the entire eastern flank of the apartment, the stunning aerie is most fortunate to have four rooms overlooking Park Avenue and to feature pretty, sunny and open views throughout. Boasting divine entertaining spaces that exude elegance and restrained grandeur, this exceptional apartment is a one of a kind, having been built to the exacting specifications of philanthropist, bibliophile, and Macy's heir, Jesse Isidor Strauss.
In particular, the fabulous corner Master Bedroom Suite with its massive marble bathroom and huge dressing room is the best of its kind, while the large and pristine Chef's Kitchen, Pantry and Breakfast Room also conveniently allow for gracious and informal dining. Other notable features include a Living Room with the most lovely bay window, a grand Dining Room, a cozy Library and two perfect guest bedrooms with en-suite baths. There are also four wood burning fireplaces, French doors throughout, abundant southern exposures and lots of original moldings. Plus stunning examples of valuable and exceedingly beautiful period boiserie and accompanying marble fireplace surrounds. Designed by the great Rosario Candela in the golden era of apartment house building, this sophisticated and chic residence, on the corner of 70th Street and Park Ave, is truly a trophy property and also simply the most delightful abode.
Furthermore, having once comprised the upper floor of an extraordinary home, the acquisition of this listing affords a unique opportunity for a buyer looking to reassemble the celebrated Strauss Duplex. As it is now possible to acquire the lower floor as well, and to restore the baronial scale and layout of one of Park Avenue's most historically important prewar coop residences.
Extremely rare and glamourous 12 room apartment perched high atop a most distinguished white-glove prewar cooperative. Impeccably appointed by the renowned design team of Aman Meeks, the residence was extensively featured in the firm's recent coffee table tome, The New Formal. Distinguished by a 95 foot long planted terrace that charmingly meanders along the entire eastern flank of the apartment, the stunning aerie is most fortunate to have four rooms overlooking Park Avenue and to feature pretty, sunny and open views throughout. Boasting divine entertaining spaces that exude elegance and restrained grandeur, this exceptional apartment is a one of a kind, having been built to the exacting specifications of philanthropist, bibliophile, and Macy's heir, Jesse Isidor Strauss. In particular, the fabulous corner Master Bedroom Suite with its massive marble bathroom and huge dressing room is the best of its kind, while the large and pristine Chef's Kitchen, Pantry and Breakfast Room also conveniently allow for gracious and informal dining. Other notable features include a Living Room with the most lovely bay window, a grand Dining Room, a cozy Library and two perfect guest bedrooms with en-suite baths. There are also four wood burning fireplaces, French doors throughout, abundant southern exposures and lots of original moldings. Plus stunning examples of valuable and exceedingly beautiful period boiserie and accompanying marble fireplace surrounds. Designed by the great Rosario Candela in the golden era of apartment house building, this sophisticated and chic residence, on the corner of 70th Street and Park Ave, is truly a trophy property and also simply the most delightful abode. Furthermore, having once comprised the upper floor of an extraordinary home, the acquisition of this listing affords a unique opportunity for a buyer looking to reassemble the celebrated Strauss Duplex.


ACTUALLY D-ALPHA-TOCOPHEROL: Beauty by Love's Vitamin E Oil is derived from 100% Edible Plant Based raw material. It's rich amber color cannot be mistaken. BPA-Free, Allergen-Free and GMO-Free. It is not an acetate or ester or synthetic (dl-alpha-tocpheryl acetate).
SCAR REPAIR: Vitamin E Oil has been know to have anti-inflammatory properties reducing the apperance of scars, stretch marks and fine lines.
HEAL WOUNDS: Vitamin E Oil has been known to assist and speed up the skins natural repair system.
DIY BEAUTY: Vitamin E Oil is one of the most common and looked for products to include in any Beauty DIY recipes as it nourishes the skin and acts as a natural persertavie in most beauty blends. Our Vitamin E Oil is exactly what you are looking for: thick goopy, dark amber and just a few drops will go a long way.
Beauty starts with a little love. Love our Vitamin E or choose between a full refund or a free replacement. Exceptional Customer Service is our priority. Order Now while at SPECIAL PRICE. Click Add to Cart. Thanks for Choosing Beauty by Love.


Orthotics are devices inserted into your footwear used to control abnormal foot function. When the foot is not functioning correctly, painful areas result. Pain can be in the feet, ankles, legs, knees, hips and/or the low back. A custom orthotic device can relieve that pain by offering support to the ligaments and the bone structures of the feet providing support all the way up the kinetic chain. Keyes To Health Custom Orthotics (inserts, shoes and sandals) can be constructed specifically to correct foot mechanics. Keyes To Health Custom Orthotics can relieve arch and heel pain while properly aligning the body from the feet up. At Keyes To Health's Pickering, ON clinic, we offer the State of the art precision custom-made orthotic medical appliances for maximum support and function.
How are Custom Orthotics different from store-bought insoles?
Most store-bought gel and fabric insoles may provide some padding, but do not address the underlying mechanical imbalances and support structures of your feet. Your foot is unique, and pre-fabricated devices are not customised to your foot. At Keyes To Health, your walking pattern, called your gait, is analysed using a computerised digital scanning system and that information, combined with a detailed health history and physical examination of your feet is used to design a customized orthotic appliance. The orthotic appliances are milled to your exact specifications at an orthotic lab located in Ontario.
Custom Orthotics are most helpful with foot and foot-related conditions. If you have bunions, flat or pronated feet, knee pain, ankle pain, hip pain or low back pain you may benefit from custom orthotics. We also have spealcial orthotics for arthritic and diabetic patients. Custom orthotics can be helpful for getting active. Many people who avoid otherwise healthy activity because of pain may find that they can exercise again once they have custom orthotics. Young and the young at heart may rediscover the renewed energy that comes with walking and exercise once they are fitted with custom orthotics.
What type of footwear can I wear with Custom Orthotics?
Custom Orthotics are compatible with almost all footwear types. There are orthotics for casual, work or sports shoes, safety boots, fancy dress shoes, runner's shoes, court shoes, golf shoes, as well as specially designed orthotics for ski and snowboard boots, and hockey and figure skates.
Your Custom Orthotics from Keyes To Health should last at least one year, perhaps up to 2 or 3 years depending on use. Extreme athletes will wear their orthotics harder than casual walkers and likely require more frequent replacements.Your feet may change over time and this too will necessitate an update.
Is there a warranty on my custom orthotics from Keyes To Health?
Absolutely! We want your Custom Orthotics to work for you. If they are not comfortable we will modify and/or refit them within the 90 day period after they have been dispensed to you. There is also a no charge follow up at the end of the two weeks period after the orthotics have been dispensed.
Do group benefit plans cover the cost of my Custom Orthotics?
Yes they do, although each plan has different amounts and rules and regulations. Please contact your insurance provider to determine your coverage. The Keyes To Health Clinic has a list of specific questions to ask your insurance provider. Please contact the clinic for this list. To ease reimbursement, upon payment, Keyes To Health will provide you with a copy of the examination findings, the computerised Gait Scan report, the diagnosis, a detailed statement outlining the type and number of custom orthotics and of course the cost amount. Some plans require a third party prescription which you may need to obtain from your family doctor.
How do I make an appointment at Keyes to Health?
Please go to the request an appointment button at the bottom of the main page of this website or go to the contact us list tab on the top of the page! We look forward to working with you.


Mr. Douglas spells big trouble for the 'Teen Wolf' crew. Find out what the physics teacher is hiding.
Someone is cracking skulls at Beacon Hills High, and it isn't the Ghost Riders. As nefarious as "Teen Wolf"'s new villains are, Scott and co. will have to divide their interests when an old evil finds its way into their hallowed halls. The students of BHHS have a shiny new distraction – this time in the form of a hot physics teacher by the name of Mr. Douglas. Pete Ploszek's character might have the teenage girls swooning, but, behind that gorgeous visage, he is hiding a bloody secret.
Jeff Davis' MTV series loves its mysteries, but the identity of the Dread Doctors' little lab experiment isn't one of them.
Douglas whips out his fangs in the latest season 6 promo, WWII flashing in the background. With that reveal floating around in the ether, Davis dropped a few teasers regarding the nazi werewolf.
Unfortunately for Beacon Hills' teenage supernatural denizens, this is one werewolf whose bite is way worse than his bark.
Unassuming in the daytime, Douglas can bite straight through a man's skull in the darkness. Scott's (Tyler Posey) pack is no longer focused on merely passing senior year – they'll be lucky if they survive to graduation day.
What's next for 'Teen Wolf'?
Currently, the Ghost Riders are on a tear, wiping innocents from existence with impunity. Now that Stiles (Dylan O'Brien) is in the wind, his friends will have to dig deep to resurrect his memory. As Lydia (Holland Roden), Malia (Shelley Hennig), and Scott tend to that aspect of the investigation, the younger generation of werewolves and chimeras will have their own issues to deal with.
"While Scott, Lydia and Malia search for lost memories of a missing friend, Corey discovers a connection between his abilities and the Wild Hunt," MTV teased.
Find out more when "Teen Wolf" airs Tuesdays at 9 p.m. ET on MTV. Click the video below to see a preview for the series' next episode.


cause for me, there is no better street camera!
Great low light shots, well done. # 3 is my favourite, but all three are good.
Nice shots. I'd agree that a Leica M is a great street camera. Here is an old picture from 1974 or so, some kids playing in the school yard of a pre-school. Taken with a Leica CL and a 40mm Summicron-C.
aj, i love how the first shot is framed by the soda bottle!
Really terrific work, Kingsfan. Bravo!
Nice shots both, but the first one is fantastic.
they are all excellent shots!
Love the first one in this series.
This is turning out to be an extraordinary thread! Fantastic work, all!


text:
Personal Injury Lawsuit
Verdicts & Settlements Archive
Verdicts & Settlements by Type
Search Verdicts & Settlements
Forklift Accident Settlement is $1 Million
2010 Personal Injury Trial Report
66 year-old-man loses foot to amputation resulting from forklift accident injury
The plaintiff was a 66 year old truck driver who had his foot run over by a forklift that was owned and operated by the defendant warehouse company. The plaintiff suffered a de-gloving and crush injury that resulted in a below the knee amputation. He has not been able to return to work.
On the day of the accident, the plaintiff performed a routine pickup of material at the defendant's facility. The plaintiff backed his truck up to the loading area and the forklift operator, an employee of the defendant, loaded the product onto the plaintiff's truck. While backing out of the truck, the forklift operator ran over the plaintiff's left leg. The plaintiff had been standing in the warehouse near his truck and in the path of travel of the forklift.
EMS personnel arrived at the scene shortly following the incident. The plaintiff was transported to the hospital, where doctors amputated the toes on his left foot. Five days later, doctors performed a second surgery, which involved an amputation of the plaintiff's leg below the knee. The plaintiff underwent three subsequent debridements of the wound and now requires the use of a prosthetic leg.
The plaintiff claimed that the defendant's employer was responsible for the negligent operation of a forklift and should have been looking where he was going and paying attention to the path of travel of his forklift. The defendant claimed that the plaintiff was also responsible for the accident as he was not paying attention to the movement of the forklift despite the plaintiff's knowledge that the forklift was going in and out loading his truck and despite the back-up alarm sounding on the forklift.
The case settled during discovery for $1,000,000. As part of the settlement, a worker's compensation lien of $165,000 was compromised with the worker's compensation insurer which also agreed to pay an additional $150,000 in lump sum settlement of future obligations.
Lubin & Meyer lawyers represented the plaintiff in this personal injury lawsuit.
Questions about an injury due to another's negligence?
Do you have questions about an injury caused by another's negligence?
Our medical malpractice lawyers are licensed to practice in: Massachusetts, New Hampshire and Rhode Island.
Return to: Verdicts & Settlements - medical malpractice case archive
Return to: Lubin & Meyer home page